CBAY : Insider Transactions for Cymabay Therapeutics, Inc.

Company Profile CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases. Co.'s pipeline includes the following clinical stage product candidates: seladelpar, a selective agonist for the peroxisome proliferator-activated receptor delta, which is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells; and MBX-2982, which targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	51,301
Total Buy Value	$0	$0	$0	$100,037
Total People Bought	0	0	0	1
Total Buy Transactions	0	0	0	1
Total Shares Sold	6,000	235,302	552,511	672,611
Total Sell Value	$191,849	$4,692,766	$8,944,114	$10,085,429
Total People Sold	1	5	6	7
Total Sell Transactions	1	14	33	36
End Date	2024-02-11	2023-11-10	2023-05-12	2022-05-12

Adjust Filter Settings

Records found: 156

Page 6 of 7

Filer's Name

Relation Title

Off-Dir-10%

Tran. Date

Form

Action

Price

Mkt Value

D/I

Shares

Holdings

Rank

3m +/-

Form

Goldfischer Carl

Director

– • –

2017-11-02

$8.66

$155,880

D/D

(18,000)

Goldfischer Carl

Director

– • –

2017-11-02

$1.72

$42,210

D/D

18,000

Emster Kurt Von

Director

– • –

2017-11-01

$9.25

$39,979

I/I

(4,320)

1,216,471

Emster Kurt Von

Director

– • –

2017-10-31

$9.27

$487,352

I/I

(52,573)

1,220,791

Emster Kurt Von

Director

– • –

2017-10-30

$9.26

$61,449

I/I

(6,636)

1,273,364

Emster Kurt Von

Director

– • –

2017-10-03

$7.81

$554,041

I/I

(70,940)

1,280,000

Emster Kurt Von

Director

– • –

2017-10-02

$7.93

$300,832

I/I

(37,936)

1,350,940

Emster Kurt Von

Director

– • –

2017-09-29

$8.04

$970,709

I/I

(120,735)

1,388,876

Emster Kurt Von

Director

– • –

2017-09-28

$8.15

$736,670

I/I

(90,389)

1,509,611

Wills Robert James

Director

– • –

2017-08-01

$6.83

$34,221

D/D

5,000

30,000

2.39

Mcwherter Charles

SVP & Chief Scientific Officer

• – –

2017-07-20

$7.42

$37,137

D/D

5,000

10,000

2.74

Shah Sujal

Interim President & CEO

• • –

2017-07-20

$7.29

$73,401

D/D

10,000

85,000

2.81

Emster Kurt Von

Director

– • –

2017-07-19

$6.50

$999,999

I/I

153,846

1,753,846

2.1

Wills Robert James

Director

– • –

2016-09-06

$2.43

$60,858

D/D

25,000

2.39

Omara Patrick J.

VP, Business Development

• – –

2016-04-15

$1.64

$8,200

D/D

5,000

5,022

2.74

Mcwherter Charles

Sr. Vice President

• – –

2016-04-15

$1.68

$5,040

D/D

3,000

5,000

2.74

Shah Sujal

Chief Financial Officer

• – –

2016-04-05

$1.39

$45,870

D/D

33,000

75,000

2.74

Shah Sujal

Chief Financial Officer

• – –

2016-04-04

$1.39

$30,580

D/D

22,000

42,000

2.74

Stein Evan A.

Director

– • –

2016-04-01

3/A

$0.00

D/D

151,880

Stein Evan A.

Director

– • –

2016-04-01

$0.00

D/D

100,000

Omara Patrick J.

VP, Business DevelopmentOffice

• – –

2016-01-26

$0.00

D/D

Goldfischer Carl

Director

– • –

2015-09-11

$2.76

$42,689

I/I

(15,467)

Goldfischer Carl

Director

– • –

2015-09-10

$2.71

$44,715

I/I

(16,500)

948

Goldfischer Carl

Director

– • –

2015-09-09

$2.76

$40,743

I/I

(14,762)

1,959

Von Emster Kurt

Director

– • –

2015-08-14

$2.70

$158,313

D/D

58,641

90,000

2.39

156 Records found	1 2 3 4 5 6 7	Page 6 of 7

Transaction Code Key:				Ownership Code Key
B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
OE	- Options Exercised	A	- Acquired
IO	- Initital Ownership	D	- Disposed

Summary:

Chart:

3m +/-: